Introduction
============

Heart failure (HF) is a chronic, long-lasting condition, the progression of which can be partially postponed, but not stopped.[@b1-ppa-7-337] The treatment strategy in HF requires the lifelong adherence to medical self-care regimes, such as: medications, dietary sodium restrictions, and self-monitoring (eg, daily weight measurements).[@b1-ppa-7-337] Although high compliance improves outcomes in HF, in everyday clinical practice it is difficult to obtain and maintain high compliance in a long-term perspective.[@b2-ppa-7-337]

The reasons for noncompliance have not been clearly established; however, there are premises arising from the studies performed in patients with other chronic diseases that noncompliance may be related to the psychological features of patients[@b3-ppa-7-337]--[@b5-ppa-7-337] and there are suggestions that psychological interventions could improve compliance among HF patients.[@b2-ppa-7-337] In this context, two psychological features seem to be of crucial importance: ie, health locus of control and the sense of self-efficacy.[@b3-ppa-7-337]--[@b5-ppa-7-337]

Health locus of control refers to the individual's beliefs regarding the control of health, whereas the sense of self-efficacy reflects the individual's belief in his/her own skills to plan and perform certain activities to attain particular aims.[@b6-ppa-7-337] None of these features have been investigated in patients with HF. Thus, the objective of this study was to examine the health control beliefs and the sense of self-efficacy in patients with stable systolic HF, also in the context of their clinical status and depressive symptoms.

Subjects and methods
====================

Study population
----------------

We examined patients with systolic HF hospitalized in the Centre for Heart Diseases, Military Hospital (Wroclaw, Poland). There were the following inclusion criteria for the study: (1) a \>6-month documented history of HF (New York Heart Association \[NYHA\] I--III classes);[@b1-ppa-7-337] (2) clinical stability with unchanged medications for ≥3 months preceding the study; and (3) left ventricular ejection fraction \< 45% as assessed by echocardiography.

Exclusion criteria comprised: (1) HF decompensation within 3 months preceding the study; (2) acute coronary syndrome and/or coronary revascularization during the 6 months preceding the study; and (3) any psychiatric abnormalities and associated therapy either at the time of examination or in the past.

The study was approved by the local ethics committee. All subjects gave written informed consent. The study was conducted in accordance with the Declaration of Helsinki.

Study protocol
--------------

Each patient underwent a physical examination with routine laboratory tests and standard transthoracic echocardiography. Plasma N-terminal pro-B type natriuretic peptide (\[NT-proBNP\] pg/mL) was measured using electrochemiluminescence on the Elecsys 1010/2010 System (Roche Diagnostics GmbH, Mannheim, Germany). Renal function was assessed using the estimated glomerular filtration rate (\[GFR\] mL/minute/1.73 m^2^), calculated from the Modification of Diet in Renal Disease equation.[@b7-ppa-7-337] Serum high-sensitive C-reactive protein (hsCRP, mg/L) was assessed using immunonephelometry (analyser no BN II, Dade Behring, Siemens AG, Munich, Germany). Afterwards, each patient completed psychological questionnaires assessing.

1.  the health locus of control, and

2.  the sense of self-efficacy.

Health locus of control (ie, the set of personal beliefs regarding the control of individual health status), was assessed using the Polish version of the Multidimensional Health Locus of Control Scale (\[MHLC\] forms A and B), originally proposed by Wallston et al[@b8-ppa-7-337] and adopted by Juczynski in 1999.[@b9-ppa-7-337] MHLC measures three possible localizations of health control: internal localization, called "internality" (internal locus of control, measured by a subscale named IHLC) and two external localizations called "powerful others externality" (measured by a subscale named PHLC) and "chance externality" (measured by a subscale named CHLC).[@b8-ppa-7-337],[@b9-ppa-7-337]

Patients with high internality (those having high scores on the IHLC subscale) believe that their health status depends only on their own behaviors.

Patients with high powerful others externality (expressed as high scores on the PHLC subscale) are convinced that their individual health status is the consequence of the actions performed by powerful people, eg, doctors, family members, friends.

Patients with high chance externality (expressed as high scores on the CHLC subscale) believe that mainly chance, fate, or luck determine their health status.[@b8-ppa-7-337],[@b9-ppa-7-337]

Each subscale is composed of six items. The answers for each item are expressed using a 6-point Likert scale, where the lowest score (1) means "strongly disagree," and the highest score (6) means "strongly agree;"[@b8-ppa-7-337],[@b9-ppa-7-337] thus, it is possible to obtain from 6 to 36 points in each subscale. The initial publication regarding these scales established the fact that they are internally consistent and concurrently valid. Patients with HF examined in the present study were compared with patients with other chronic diseases and healthy subjects (based on values from the instructions for the MHLC).[@b8-ppa-7-337],[@b9-ppa-7-337]

The sense of self-efficacy was measured using the Polish version of the Generalized Self-Efficacy Scale (GSES) originally developed by Schwarzer and Jerusalm,[@b10-ppa-7-337] and also adopted by Juczynski.[@b9-ppa-7-337] GSES measures how an individual judges his/her own competence in order to complete tasks (by the means of behaviors, thoughts, and emotions) and reach desired goals. GSES includes ten items, each answered with a 4-point Likert type scale, where 1 means "not at all true" and 4 means "exactly true". Validity and internal consistency of a Polish version has been confirmed in a group of 496 healthy adults.[@b9-ppa-7-337] Normalization enables us to transform the results of the GSES to sten scores. A sten score indicates an individual's approximate position in the context of the values characteristic for the normal, general population.[@b17-ppa-7-337] Sten scores range from 1 to 10. GSES scores assigned to 1--3, 4--6, and 7--10 sten scores are interpreted as the low, moderate, and high sense of self-efficacy, respectively.[@b9-ppa-7-337]

Afterwards, each patient completed the Beck Depression Inventory (\[BDI\] version Ia)[@b11-ppa-7-337] for assessing depressive symptoms. The BDI is a self-administered, 21-item self-report inventory, with the possibility to differentiate depressive symptoms as cognitive--affective (the first 13 items of the BDI) and somatic (the remaining items), using the Polish version of the BDI. The BDI score ≤ 10 points indicated no depressive symptoms, whereas the BDI score ≥ 16 suggested the presence of at least mild depressive symptoms.[@b12-ppa-7-337]

Statistical analyses
--------------------

Normally distributed continuous variables were presented as means ± standard deviations. The intergroup differences were tested using Student's *t*-test. Variables with a skewed distribution were expressed as medians with lower and upper quartiles, and were log transformed in order to normalize their distributions. The categorical variables were expressed as numbers with percentages. The inter-group differences were tested using the χ^2^ test. Relationships between the analyzed variables were assessed using Pearson's correlatory coefficients (for normally distributed continuous variables) or Spearman's rank correlatory coefficients (for variables with a skewed distribution or categorical variables).

A value of *P* \< 0.05 was considered statistically significant.

Results
=======

Sixty-six patients with systolic HF were enrolled in the study. The majority of them were males, classified in the NYHA I--II classes, and received standard pharmacotherapy ([Table 1](#t1-ppa-7-337){ref-type="table"}). A BDI score ≥ 16 was recorded in approximately 40% of the examined subjects.

Health locus of control and the sense of self-efficacy in patients with HF
--------------------------------------------------------------------------

The distribution of MHLC scores recorded in patients with HF was presented in [Table 2](#t2-ppa-7-337){ref-type="table"}. The most pronounced localization of health control in examined patients with HF were powerful others externality and internality. Low, moderate, and high sense of self-efficacy was found in 2%, 14%, and 77% of patients with HF, respectively.

Health locus of control and the sense of self-efficacy in patients with HF compared with patients with other chronic diseases and healthy subjects
--------------------------------------------------------------------------------------------------------------------------------------------------

Internality was similar in patients with HF, patients with diabetes, men after myocardial infarction, and women after mastectomy (all *P* \> 0.2), and was lower as compared to healthy subjects (*P* \< 0.05) ([Table 3](#t3-ppa-7-337){ref-type="table"}).

Powerful others externality was more pronounced in patients with HF as compared to patients with other chronic diseases and healthy people (all *P* \< 0.05), in spite of women after mastectomy, who had higher PHLC scores (*P* \< 0.05) ([Table 3](#t3-ppa-7-337){ref-type="table"}).

Chance externality was similar in patients with chronic diseases, including those with HF, renal failure, men after myocardial infarction, and women after mastectomy (all *P* \> 0.2). In patients with HF, chance externality was less pronounced than among healthy subjects (*P* \< 0.05) ([Table 3](#t3-ppa-7-337){ref-type="table"}).

Patients with HF had the highest sense of self-efficacy as compared to the other groups of patients with chronic diseases and healthy controls. Patients with systolic HF with the higher sense of self-efficacy had also more pronounced internality (r = 0.29, *P* = 0.02).

Associations between health control and self-efficacy, and clinical status of patients with HF
----------------------------------------------------------------------------------------------

The magnitude of internality was inversely related to plasma NT-proBNP in patients with HF (r = −0.43, *P* = 0.03). There were no other relationships between health control localization, the sense of self-efficacy, and any clinical variable (all *P* \> 0.2).

Associations between health control and self-efficacy, and depressive symptoms of patients with HF
--------------------------------------------------------------------------------------------------

Patients with systolic HF with higher sense of self-efficacy were characterized by less pronounced depressive symptoms (r = −0.26, *P* = 0.04), both affective-cognitive (r = 0.32, *P* = 0.01) and somatic depressive symptoms (r = −0.28, *P* = 0.03).

Discussion
==========

As far as we are aware, this is the first report providing evidence on the localization of health control and the sense of self-efficacy in patients with stable systolic HF living in contemporary Poland. Both features seem to be important in the context of the HF management and the level of self-care among these patients. There are only a few studies focused on the localization of health control and the sense of self-efficacy in patients with stable systolic HF in the international literature.[@b12-ppa-7-337]--[@b15-ppa-7-337]

The localization of health control is important in the context of coping with chronic diseases. Internality and powerful others externality are positively related to drug compliance in patients with schizophrenia,[@b15-ppa-7-337] internality predicts better adherence to treatment recommendations among patients with chronic pain,[@b16-ppa-7-337] as well as among injured athletes.[@b17-ppa-7-337] High self-efficacy is related to self-care behaviors in kidney transplant recipients,[@b7-ppa-7-337] in patients with diabetes,[@b18-ppa-7-337] and also in healthy people.[@b19-ppa-7-337]

It seems that patients with HF are unique with regard to these two psychological features as compared to the other groups of patients with chronic diseases living in Poland. The most pronounced localization of health control in examined patients with HF was powerful others externality, which may suggest that they could potentially seriously take into consideration medical advice from physicians. The magnitude of internality was relatively high, indicating that they could also take substantial responsibility for their health status. Most importantly, patients with HF were characterized by much higher sense of self-efficacy as compared to the other groups of patients.[@b9-ppa-7-337] Both features should be taken into consideration while planning modern strategies aiming to improve self-care and compliance in patients with HF.

In the present study, we found no associations between the health-control localization, the sense of self-efficacy, and clinical parameters, in spite of the inverse relationship between plasma NT-proBNP (a parameter which reflects the severity of the disease; higher NT-proBNP is characteristic of more advanced HF) and internality. This may be related to the common awareness in contemporary societies that the most important causes of cardiovascular diseases (eg, HF) are the consequence of unhealthy lifestyles,[@b20-ppa-7-337] which is related to the common conscience of the individual responsibility for one's health status.

Depressive symptoms are common in patients with HF, and are related to the severity of the disease.[@b12-ppa-7-337] In the present study, the higher sense of self-efficacy was accompanied by less marked depressive symptoms in patients with HF, which is consistent with previous studies in patients with chronic diseases[@b18-ppa-7-337],[@b21-ppa-7-337] as well as among healthy people.[@b22-ppa-7-337] Importantly, the sense of self-efficacy can be a mediator in the reaction to strong stressors (eg, chronic disease and related debilitating symptoms, such as dyspnea in HF) and the occurrence of depressive symptoms.[@b23-ppa-7-337] It has been demonstrated that the increase in self-efficacy due to a modeling intervention in patients with HF was followed by a significant improvement in clinical status (eg, a reduction of exercise intolerance expressed by an increased peak oxygen consumption).[@b24-ppa-7-337]

Limitations
-----------

We are aware that our study has some limitations related to the applied methodology, which need to be acknowledged.

Firstly, our results may be affected by selection bias, as there is no doubt that there are differences in psychological features between those who agree and disagree to participate in this kind of study, and we will never be able to familiarize ourselves with the psychological features of subjects who refuse to fill in psychological questionnaires. Moreover, the study was performed among hospitalized patients. It is likely that the results obtained among outpatient clinic patients with HF, who were not included in the present study, would be different. As a result, our findings cannot be generalized beyond the studied group.

Secondly, all applied questionnaires are typical self-reported measures, which are related with a potential risk of misstatement.

Thirdly, the present study constitutes a preliminary report regarding two psychological features that may be related to self-care and compliance with medical regimes in patients with HF. We did not analyze an actual rate of compliance among examined patients, and undoubtedly such analyses should be performed as the continuation of our project.

Conclusion
==========

Patients with systolic HF demonstrate a conviction that other people, including physicians, have a large influence on their health status, and at the same time are aware of the efficacy of their own activities in coping with the disease. Such a configuration of psychological features seems to be beneficial in the context of the developing modern strategies, which (due to the improved cooperation between the physicians and the patients) could enhance compliance in patients with HF.
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###### 

Baseline characteristics of 66 examined patients with systolic heart failure

  Variables                              Patients with HF (n = 66)
  -------------------------------------- ----------------------------
  Age (years)                            61 ± 11
  Men (n \[%\])                          60 (91%)
  BMI (kg/m^2^)                          28.5 ± 4.1
  Ischemic HF etiology (n \[%\])         63 (95%)
  NYHA classes I/II/II (n \[%\])         11 (17%)/39 (59%)/16 (24%)
  LVEF (%)                               32 ± 12
  NT-proBNP (pg/mL)                      1251 (591--3923)
  Hypertension (n \[%\])                 31 (47%)
  DM (n \[%\])                           23 (35%)
  Hemoglobin (g/dL)                      18.8 ± 1.7
  eGFR-MDRD (mL/minute/1.73 m^2^)        71.2 ± 22.7
  Sodium (mmol/L)                        140 ± 3
  hsCRP (mg/L)                           3.34 (1.50--9.23)
  BDI score                              13 ± 9
  BDI-scores: ≤10/11--15/≥16 (n \[%\])   25 (38%)/13 (20%)/28 (42%)
  BDI score for C-A                      6 ± 6
  BDI score for S                        8 ± 4
  **Treatment**                          
  ACEI and/or ARB (n \[%\])              50 (75%)
  Beta-blocker (n \[%\])                 57 (86%)
  Aldosterone antagonist (n \[%\])       34 (51%)
  Digoxin (n \[%\])                      12 (18%)
  Loop diuretic (n \[%\])                25 (38%)
  Thiazide diuretic (n \[%\])            21 (32%)
  Statin (n \[%\])                       48 (73%)
  ASA (n \[%\])                          35 (52%)

**Note:** Results are presented as a mean ± standard deviation, a median with lower and upper quartiles, or a number with a percentage.

**Abbreviations:** ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor antagonist; ASA, acetylsalicylic acid; BDI, Beck Depression Inventory; BMI, body mass index; (C-A), BDI subscale for cognitive and affective depressive symptoms; DM, diabetes mellitus; eGFR-MDRD, estimated glomerular filtration rate calculated using the MDRD formula; HF, heart failure; hsCRP, high sensitivity C-reactive protein; LVEF, left ventricular ejection fraction; MDRD, Modification of Diet in Renal Disease; NT-proBNP, N-terminal pro-B type natriuretic peptide; NYHA, New York Heart Association; S, BDI subscale for somatic symptoms of depression.

###### 

Distribution of scores in three subscales of the Multidimensional Health Location of Control scale in 66 patients with systolic heart failure

![](ppa-7-337t1)

**Abbreviations:** CHLC, a subscale measuring external location of health control focused on the role of luck; IHLC, a subscale measuring an internal location of health control; max, maximum value; MHLC, Multiple Health Control Localization scale; min, minimum value; PHLC, a subscale measuring external location of health control focused on the role of other, powerful people; SD, standard deviation of a mean.

###### 

Mean values of MHLC and GSES scores in patients with systolic heart failure, patients with other chronic diseases, and healthy subjects

  Variables       Patients with HF n = 66   Patients with other chronic diseases[@b9-ppa-7-337]   Healthy subjects[@b9-ppa-7-337]                                                                                                                                                                             
  --------------- ------------------------- ----------------------------------------------------- -------------------------------------------------- -------------------------------------------------- -------------------------------------------------- -------------------------------------------------- --------------------------------------------------
  IHLC (points)   26 ± 5                    26 ± 6                                                24 ± 3[\*](#tfn5-ppa-7-337){ref-type="table-fn"}   26 ± 4                                             25 ± 5                                             28 ± 5[\*](#tfn5-ppa-7-337){ref-type="table-fn"}   --
  PHLC (points)   29 ± 5                    26 ± 7[\*](#tfn5-ppa-7-337){ref-type="table-fn"}      25 ± 4[\*](#tfn5-ppa-7-337){ref-type="table-fn"}   25 ± 5[\*](#tfn5-ppa-7-337){ref-type="table-fn"}   31 ± 5[\*](#tfn5-ppa-7-337){ref-type="table-fn"}   20 ± 6[\*](#tfn5-ppa-7-337){ref-type="table-fn"}   --
  CHLC (points)   22 ± 6                    20 ± 7[\*](#tfn5-ppa-7-337){ref-type="table-fn"}      22 ± 5                                             22 ± 6                                             22 ± 6                                             18 ± 6[\*](#tfn5-ppa-7-337){ref-type="table-fn"}   --
  GSES (points)   32 ± 4                    28 ± 5[\*](#tfn5-ppa-7-337){ref-type="table-fn"}      27 ± 5[\*](#tfn5-ppa-7-337){ref-type="table-fn"}   27 ± 6[\*](#tfn5-ppa-7-337){ref-type="table-fn"}   30 ± 4[\*](#tfn5-ppa-7-337){ref-type="table-fn"}   --                                                 27 ± 5[\*](#tfn5-ppa-7-337){ref-type="table-fn"}

**Notes:** Results are presented as mean ± standard deviations.

*P* \< 0.05 -- the particular group versus patients with systolic HF.

**Abbreviatons:** CHLC, a subscale measuring external location of health control focused on the role of luck; DM, diabetes mellitus; GSES, Generalized Self-Efficacy Scale; HF, heart failure; IHLC, a subscale measuring an internal location of health control; MHLC, Multiple Health Control Localization scale; MI, myocardial infarction; PHLC, a subscale measuring external location of health control focused on the role of other, powerful people.
